TetanustetanusNCT07724379
A Study of Tetanus Antibody of Healthy Adults
An observational study of Tetanus, run by Peking University First Hospital at 1 site in China.
Trial summary
The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is: 1. Analysis of tetanus antibody distribution across different age groups 2. Evaluation of the TQS method for determining antibody status 3. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Tetanus
- How many people
- 2,009 participants
- Where
- 1 siteChina
- Study dates
- 4 May 2025to 15 May 2026
- How long will I take part?
- 6 Months
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This study will enroll healthy adults aged 18 years who reside in Beijing. Participants will be recruited voluntarily from the general population. Both males and females are eligible. Participants must be willing to provide a blood sample and complete a brief questionnaire regarding their vaccination history. Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded.
Who may be able to join
- Voluntarily sign the informed consent form；
- Be aged 18 years or older；
- Be willing to provide a blood sample for biochemical testing
Who cannot join
- Receipt of immunoglobulin, blood, or blood products within 6 months prior to enrollment；
- Refusal to provide tetanus vaccination history (including vaccination records, CDC vaccine administration registry, or subject's recall)；
- Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded
Trial locations and contacts
1 site in 1 country.
China1 site
Peking University First Hospital
Beijing, Beijing Municipality, 100034
About this study
Official title: A Prospective Study of Tetanus Antibody Protective Efficacy in Healthy Populations in Beijing
The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is:
- Analysis of tetanus antibody distribution across different age groups
- Evaluation of the TQS method for determining antibody status
- Correlation between primary vaccination history and tetanus antibody concentrations Blood samples were voluntarily provided by adult healthy participants for tetanus antibody analysis over a continuous collection period of more than one year.
- Conditions
- Tetanus
- Keywords
- Healthy Adults, Vaccination, Protective Efficacy, Observational Study, TQS, tetanus
- Medical subject headings
- Tetanus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| age group | 20-29;30-39;40-49;50-59;≥60 | |
| gender group | male; female | |
| education background | high school; bachelor; master; et al | |
| primary vaccination | ≥3 doses TTCV; < 3 doses TTCV; unknown | |
| last TTCV dose duration | ≤5 year;5-10 year; >10 year; unkown |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tetanus Antibody Level
Single blood draw
Measured: Baseline (single blood draw at enrollment)
Secondary outcomes (1)
tetanus antibody level by TQS/mTQS method
at baseline
Measured: Baseline (single blood draw at enrollment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2026
- Study start4 May 2025
- Primary completion3 Mar 2026
- Study completion15 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TetanusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 2,009 participants (actual)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Liu Si, Peking University First Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07724379
- Sponsor's protocol ID
- 2024R524
- Other IDs
- 2024IR10
- Acronym
- tetanus
- Status last verified
- Jul 2026
- First submitted
- 1 Jul 2026
- Last updated
- 24 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided